Advanced Oncotherapy PLC Update on Distribution Agreement Payment

Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to the Company’s announcement of 3 April 2018, the Company has received from Yantai Cipu, through its affiliated entity Liquid Harmony, £6.5 million as the first payment relating to the Distribution Agreement announced on 7 December 2017. The Company has been advised by Liquid Harmony that the balance of £10.0 million will be received in the coming weeks.

The proceeds from the above payment will be used towards the repayment of the loan made to the Company by Blackfinch Investment Ltd (“Blackfinch”) through its subsidiary Henslow Trading Limited, for a total aggregate nominal value, including interest, of £6.7 million (the “Loan”).

In addition, the Company and Blackfinch have agreed to set at 70p the exercise price of the batch of 1,000,000 warrants issued by the Company to Blackfinch on 24 March 2017 in relation to the Loan.

After repayment of the Loan by the Company, Blackfinch has agreed to release the security it held on the Company’s lease for 141-143, Harley Street and on certain other equipment of the Company. All the assets of the Company are now free of any security arrangement.

Commenting, Nicolas Serandour, CEO of Advanced Oncotherapy Plc, said: “We appreciate the flexibility demonstrated by Blackfinch who extended the maturity of the Loan on the same terms. We have been impressed by their seriousness in understanding our technology.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Advanced Oncotherapy Plc

    More articles like this

    Hardman & Co

    Advanced Oncotherapy: Leveraging the modularity of LIGHT

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly de-risked the

    Hardman & Co

    Advanced Oncotherapy funded through to clinical events

    AVO’s goal is to deliver an affordable and novel proton therapy (PT) system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly de-risked through important

    Hardman & Co

    Advanced Oncotherapy Rapidly changing to commercial execution

    Advanced Oncotherapy plc (LON:AVO) is the topic of discussion when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the interesting developments being made at the company, commercial deals, brings us up to date

    Hardman & Co

    Advanced Oncotherapy Confidence in LIGHT gaining momentum

    The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked